Earnings ·
Parabilis Medicines reported second quarter 2026 financial results and business updates
PBLSParabilis Medicines, Inc.
Parabilis Medicines reported second quarter 2026 financial results and business updates. The company announced a strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, receiving $125 million in upfront consideration and equity investment, with potential for up to $2.2 billion in milestone payments plus tiered royalties. Parabilis completed an upsized initial public offering of common stock at $20.00 per share, raising $770.5 million before expenses, and began trading on Nasdaq under the ticker PBLS on June 10, 2026. The company ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, expected to fund operations into 2030. Research and development expenses were $39.4 million, while general and administrative expenses were $11.7 million, resulting in a net loss of $52.5 million for the quarter. The company is a clinical-stage biopharmaceutical company focused on developing medicines that target historically undruggable intracellular proteins using its proprietary Helicon platform.